Latest news and press releases about PolyPid Ltd. (PYPD): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials.
Price
| Price | $5.21 |
| Market Cap | $99M |
| Exchange | NASDAQ |
| Country | IL |
Valuation Ratios
| Price / Book | 21.89 |
| EV / EBITDA | -3.18 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -311.07% |
| Return on Invested Capital | 11.71% |
| Return on Assets | -206.78% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ANVS · ATNM · BCAB · BTAI · CELU · EVAX · MAIA
Explore sector: Healthcare · Biotechnology
More sections of PYPD: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks